EverSource Wealth Advisors’s Spyre Therapeutics SYRE Stock Holding History

EverSource Wealth Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.6K	Buy	345 +266	+337%	+$19.4K	﹤0.01%	2130
2026 Q1	$3.98K	Buy	79 +14	+22%	+$528	﹤0.01%	3363
2025 Q4	$2.13K	Hold	65	–	–	﹤0.01%	3483
2025 Q3	$1.09K	Hold	65	–	–	﹤0.01%	3739
2025 Q2	$973	Buy	65 +41	+171%	+$607	﹤0.01%	3744
2025 Q1	$387	Buy	24 +16	+200%	+$333	﹤0.01%	3542
2024 Q4	$186	Buy	+8	New	+$235	﹤0.01%	3445

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

EverSource Wealth Advisors's SYRE Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Spyre Therapeutics (SYRE) stake by 337% in Q2 2026, buying an estimated $19.4K and bringing the position to 345 shares worth $30.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2130.

EverSource Wealth Advisors first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

EverSource Wealth Advisors held 345 shares of Spyre Therapeutics worth $30.6K as of Q2 2026.
EverSource Wealth Advisors bought 266 Spyre Therapeutics shares in Q2 2026, an estimated $19.4K.
Spyre Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2130 holding.
EverSource Wealth Advisors first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.